Snowball logo
logo
ABCZ_logo

Abcam plc

ABCZF • PINK
$22.25$0.00  (0%)
Estimate
P/E
2,225
EPS
0.01
Beta
0.863
About the company
Ticker
ABCZF
ISIN
Country
United Kingdom
Sector (GICS)
Healthcare
Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.

Frequently asked questions

What sector does Abcam plc (ABCZF) operate in?

Abcam plc belongs to the Healthcare sector and operates in the industry.

What is Abcam plc (ABCZF) current stock price?

As of the latest data, Abcam plc stock price is $22.25, with a previous close of $22.25.

What is Abcam plc (ABCZF) current market capitalization?

Abcam plc market cap is approximately 5.12 billion.

What is Abcam plc (ABCZF) Earnings Per Share (EPS)?

The trailing EPS is $0.01.

What is Abcam plc (ABCZF) Price-to-Earnings (P/E) ratio?

Abcam plc current P/E ratio is 2,225.

Does Abcam plc (ABCZF) pay dividends?

No. Abcam plc does not pay a dividend.

What is Abcam plc (ABCZF) beta (volatility) score?

Abcam plc has a beta of 0.863, meaning its volatility is roughly in line with the market.